Inhibikase Therapeutics, Inc. Elects Richard Fante And Patrick Vink To Its Board Of Directors

ATLANTA and CAMBRIDGE, Mass., May 4, 2015 /PRNewswire/ -- Inhibikase Therapeutics, Inc. announces the election of Richard Fante, former President of AstraZeneca U.S.A. and CEO of AstraZeneca North America and the election of Patrick Vink, former Executive Vice President and COO of Cubist Pharmaceuticals, to its Board of Directors.  Anthony Zook has stepped down from the Board due to his new role as CEO of Innocoll AG.

Rich Fante serves as President of RF Consulting LLC since April 11, 2013, a private pharmaceutical consulting business that advises clients on commercial assessments and go-to-market strategies. Prior to founding RF Consulting, Mr. Fante spent over nineteen years at AstraZeneca Pharmaceuticals in the United States. He served most recently as President U.S.A. and CEO North America and Regional Vice President for the Americas.  Prior to assuming his role as President AstraZeneca U.S.A., Mr. Fante served as the head of Brand Strategy and Portfolio Operations at AstraZeneca. Before joining AstraZeneca in January 1995, Mr. Fante worked at Lederle Laboratories where he started his career as a sales representative.  Mr. Fante served as Board Chairman of the National Pharmaceutical Council (2012) and was a member of the Institute of Medicine of the National Academies of Science Roundtable on Value and Science.  Mr. Fante holds a BA in Biology from Princeton University and an MBA from the University of North Carolina Chapel Hill.

Patrick Vink, M.D., M.B.A., is currently an advisor to the pharmaceutical industry and joins the Inhibikase Board following 3+ years at Cubist Pharmaceuticals, where he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management. He joined Cubist in 2012 as Senior Vice-president and Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink coordinated all hospital business of the company. He joined Mylan in 2008 and established the company's operations in Switzerland, which were the basis of a number of global functions. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice-President International Sales for Biogen; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthelabo. Dr. Vink has served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his MBA in 1992 at the University of Rochester.

"I am extremely excited about joining this talented and experienced Board and especially pleased to be working alongside Patrick Vink," noted Rich Fante.  "Together, we will help Inhibikase achieve the full commercial potential of its pipeline and improve the lives of the patients it serves."

"Joining the Board of Inhibikase together with Rich Fante at  an important  point in the growth company is a privilege to me. The promise the product pipeline of Inhibikase for patients is very meaningful and I look forward working with Board and management of the company advancing the growth of the company," said Patrick Vink

"As Inhibikase will enter the clinic this year with a full commercial development strategy being deployed, the addition of commercial development and brand development managers like Rich and Patrick will continue the Company's transition from a research engine into an integrated biopharmaceutical company.  Rich and Patrick bring complementary expertise in the U.S. and European markets where Inhibkase's lead product for PML will find its strongest placement," said Company President & CEO Dr. Milton Werner.

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases.  Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action.  The Company's host-targeting strategy using clinically validated targets treat infectious disease with a low likelihood of stimulating resistance.  Founded in 2008 and headquartered in Atlanta, Georgia with offices in Cambridge, Massachusetts, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML), BK-virus associated nephropathy (PVAN), fungal and bacterial pneumonias as well as medical countermeasures for biodefense.  Its RAMP technology is developing next generation small molecule inhibitors suitable for treatment of infections and certain cancers using single agents at a fixed dose.

SOURCE Inhibikase Therapeutics, Inc.

Related Links

http://www.inhibikase.com